.jpeg)
Akums launches an enhanced Gabapentin ER for postherpetic neuralgia, using sustained-release technology to improve pain control, once-daily dosing and patient adherence in India.
GSK Nucala has moved a step closer to European approval after the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the drug for adults with uncontrolled COPD marked by raised blood eosinophils.
Pfizer’s HER2-targeted therapy TUKYSA delivered a strong boost in first-line maintenance treatment for HER2-positive metastatic breast cancer, marking a major advance in today’s data from the Phase 3 HER2CLIMB-05 trial.
.png)
Zydus Lifesciences Ltd. has launched Zyrifa, a 120 mg subcutaneous biosimilar of the monoclonal antibody Denosumab. The new product increases the number of cancer patients who can receive advanced treatment of bone-care which is cheape...
Novo Nordisk has officially closed its acquisition of Akero Therapeutics, marking a major move in the race to develop next-generation treatments for metabolic liver diseases. The deal, first announced on October 9, 2025, is now fully completed...
India’s rising weight burden is pushing healthcare forward, and Agilus Diagnostics is stepping in with a bold move. The company has rolled out its new obesity test suite, built to give clinicians deeper insight into insulin resistance, metabolic...
Bayer’s investigational MRI contrast agent gadoquatrane is drawing industry attention today after new pediatric data strengthened its safety and performance profile. The company revealed fresh results from its QUANTI Pediatric study at the RSNA...
Drug-maker Lupin said on December 5, 2025, that it has received tentative approval from the US Food and Drug Administration (USFDA) for its generic version of Siponimod Tablets. The approved strengths are 0.25 mg, 1 mg, and 2 mg. These tablets...
.jpeg)
Granules India reported that its subsidiary in the U.S., with step-down operations, Granules Consumer Health, LLC, has passed a Good Manufacturing Practice (GMP) inspection conducted by the U.S. Food and Drug Administration (FDA) with zero observatio
.png)
Ciplostem, launched today by Cipla in partnership with Stempeutics Research, signals a strong move into orthobiologic medicine. The new MSC therapy enters the market as India faces a fast-growing burden of knee osteoarthritis, now affecting more...
.jpg)
.jpg)
, CDSCO.jpg)